BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lewitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics: Levodopa Pharmacokinetics and Pharmacodynamics. Mov Disord 2015;30:64-72. [DOI: 10.1002/mds.26082] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 16.5] [Reference Citation Analysis]
Number Citing Articles
1 Choi JW, Kim S, Yoo JS, Kim HJ, Kim HJ, Kim BE, Lee EH, Lee YS, Park JH, Park KD. Development and optimization of halogenated vinyl sulfones as Nrf2 activators for the treatment of Parkinson's disease. Eur J Med Chem 2021;212:113103. [PMID: 33387904 DOI: 10.1016/j.ejmech.2020.113103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Fabbri M, Rosa MM, Ferreira JJ. Clinical pharmacology review of opicapone for the treatment of Parkinson's disease. Neurodegenerative Disease Management 2016;6:349-62. [DOI: 10.2217/nmt-2016-0022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
3 Santos García D, Labandeira Guerra C, Yáñez Baña R, Cimas Hernando MI, Cabo López I, Paz Gonález JM, Alonso Losada MG, González Palmás MJ, Martínez Miró C. Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study. Brain Sci 2021;11:316. [PMID: 33801565 DOI: 10.3390/brainsci11030316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
4 Roycroft M, Abdelhafiz AH, Rose J. Patient-controlled variable dosing of levodopa for Parkinson's disease. Age Ageing 2020;49:305-6. [PMID: 31985772 DOI: 10.1093/ageing/afz167] [Reference Citation Analysis]
5 Lewitt PA. At last, a randomised controlled trial of apomorphine infusion. The Lancet Neurology 2018;17:732-3. [DOI: 10.1016/s1474-4422(18)30284-9] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhao C, Li H, Zhao X, Liu Z, Zhou P, Liu Y, Feng M. Heat shock protein 60 affects behavioral improvement in a rat model of Parkinson’s disease grafted with human umbilical cord mesenchymal stem cell-derived dopaminergic-like neurons. Neurochem Res 2016;41:1238-49. [DOI: 10.1007/s11064-015-1816-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
7 Solís O, García-Sanz P, Herranz AS, Asensio MJ, Moratalla R. L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum. Neurotox Res 2016;30:67-75. [PMID: 26966009 DOI: 10.1007/s12640-016-9612-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
8 Wang C, Deng H, Wang D, Wang J, Huang H, Qiu J, Li Y, Zou T, Guo L. Changes in metabolomics and lipidomics in brain tissue and their correlations with the gut microbiome after chronic food-derived arsenic exposure in mice. Ecotoxicol Environ Saf 2021;228:112935. [PMID: 34801923 DOI: 10.1016/j.ecoenv.2021.112935] [Reference Citation Analysis]
9 Leung C, Rascol O, Fabbri M. Opicapone for Parkinson's disease: clinical evidence and future perspectives. Neurodegener Dis Manag 2021;11:193-206. [PMID: 33745288 DOI: 10.2217/nmt-2021-0006] [Reference Citation Analysis]
10 Ogura J, Miyauchi S, Shimono K, Yang S, Gonchigar S, Ganapathy V, Bhutia YD. Carbidopa is an activator of aryl hydrocarbon receptor with potential for cancer therapy. Biochemical Journal 2017;474:3391-402. [DOI: 10.1042/bcj20170583] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 LeWitt PA. New levodopa therapeutic strategies. Parkinsonism Relat Disord 2016;22 Suppl 1:S37-40. [PMID: 26459662 DOI: 10.1016/j.parkreldis.2015.09.021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
12 Cortés A, Moreno E, Rodríguez-Ruiz M, Canela EI, Casadó V. Targeting the dopamine D3 receptor: an overview of drug design strategies. Expert Opin Drug Discov 2016;11:641-64. [PMID: 27135354 DOI: 10.1080/17460441.2016.1185413] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
13 Post MR, Lieberman OJ, Mosharov EV. Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease? Front Neurosci 2018;12:161. [PMID: 29593491 DOI: 10.3389/fnins.2018.00161] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
14 Luinstra M, Rutgers W, van Laar T, Grasmeijer F, Begeman A, Isufi V, Steenhuis L, Hagedoorn P, de Boer A, Frijlink HW. Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson's disease. Ther Adv Chronic Dis 2019;10:2040622319857617. [PMID: 31258882 DOI: 10.1177/2040622319857617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
15 Mundt-petersen U, Odin P. Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms. Nonmotor Parkinson’s: The Hidden Face - Management and the Hidden Face of Related Disorders. Elsevier; 2017. pp. 1019-44. [DOI: 10.1016/bs.irn.2017.05.036] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Lipp MM, Batycky R, Moore J, Leinonen M, Freed MI. Preclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinsons disease. Science Translational Medicine 2016;8:360ra136-360ra136. [DOI: 10.1126/scitranslmed.aad8858] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 5.5] [Reference Citation Analysis]
17 Paik J. Levodopa Inhalation Powder: A Review in Parkinson's Disease. Drugs 2020;80:821-8. [PMID: 32319076 DOI: 10.1007/s40265-020-01307-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
18 Deng H, Ma Z. Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice. Food Funct 2021. [PMID: 34342315 DOI: 10.1039/d1fo01360b] [Reference Citation Analysis]
19 You H, Mariani LL, Mangone G, Le Febvre de Nailly D, Charbonnier-Beaupel F, Corvol JC. Molecular basis of dopamine replacement therapy and its side effects in Parkinson's disease. Cell Tissue Res 2018;373:111-35. [PMID: 29516217 DOI: 10.1007/s00441-018-2813-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
20 Lotia M, Jankovic J. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother 2016;17:895-909. [PMID: 26830844 DOI: 10.1517/14656566.2016.1149163] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
21 Neganova ME, Aleksandrova YR, Sukocheva OA, Klochkov SG. Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. Semin Cancer Biol 2022:S1044-579X(22)00155-9. [PMID: 35779712 DOI: 10.1016/j.semcancer.2022.06.011] [Reference Citation Analysis]
22 Tan WH, Bird LM, Sadhwani A, Barbieri-Welge RL, Skinner SA, Horowitz LT, Bacino CA, Noll LM, Fu C, Hundley RJ, Wink LK, Erickson CA, Barnes GN, Slavotinek A, Jeremy R, Rotenberg A, Kothare SV, Olson HE, Poduri A, Nespeca MP, Chu HC, Willen JM, Haas KF, Weeber EJ, Rufo PA. A randomized controlled trial of levodopa in patients with Angelman syndrome. Am J Med Genet A 2018;176:1099-107. [PMID: 28944563 DOI: 10.1002/ajmg.a.38457] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
23 Berry TM, Moustafa AA. A novel treatment strategy to prevent Parkinson's disease: focus on iron regulatory protein 1 (IRP1). Int J Neurosci 2021;:1-10. [PMID: 33535005 DOI: 10.1080/00207454.2021.1885403] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 de Kruijf W, Ehrhardt C. Inhalation delivery of complex drugs-the next steps. Curr Opin Pharmacol 2017;36:52-7. [PMID: 28846876 DOI: 10.1016/j.coph.2017.07.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
25 Gungabissoon U, Kirichek O, El Baou C, Galwey N. Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson's disease. Pharmacoepidemiol Drug Saf 2020;29:591-8. [PMID: 32153056 DOI: 10.1002/pds.4986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 An H, Heo JY, Lee CJ, Nam MH. The Pathological Role of Astrocytic MAOB in Parkinsonism Revealed by Genetic Ablation and Over-expression of MAOB. Exp Neurobiol 2021;30:113-9. [PMID: 33972465 DOI: 10.5607/en21007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Chamberlain R, Windolf H, Burckhardt BB, Breitkreutz J, Fischer B. Embedding a Sensitive Liquid-Core Waveguide UV Detector into an HPLC-UV System for Simultaneous Quantification of Differently Dosed Active Ingredients during Drug Release. Pharmaceutics 2022;14:639. [DOI: 10.3390/pharmaceutics14030639] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
28 Carrarini C, Russo M, Dono F, Di Pietro M, Rispoli MG, Di Stefano V, Ferri L, Barbone F, Vitale M, Thomas A, Sensi SL, Onofrj M, Bonanni L. A Stage-Based Approach to Therapy in Parkinson's Disease. Biomolecules 2019;9:E388. [PMID: 31434341 DOI: 10.3390/biom9080388] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
29 Weitzel J, Langer K, Rose O. Effects of Generic Exchange of Levodopa Medication in Patients With Parkinson Disease. J Patient Saf 2022. [PMID: 35532994 DOI: 10.1097/PTS.0000000000001015] [Reference Citation Analysis]
30 Tran TN, Vo TNN, Frei K, Truong DD. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors. J Neural Transm (Vienna) 2018;125:1109-17. [PMID: 29971495 DOI: 10.1007/s00702-018-1900-6] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
31 Leal Rato M, Rascol O, Ferreira JJ. The "long and winding road" of the disease-modifying effects of levodopa has not ended yet. Mov Disord 2020;35:397-9. [PMID: 31872511 DOI: 10.1002/mds.27961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cai M, Chai S, Xiong T, Wei J, Mao W, Zhu Y, Li X, Wei W, Dai X, Yang B, Liu W, Shu B, Wang M, Lu T, Cai Y, Zheng Z, Mei Z, Zhou Y, Yang J, Zhao J, Shen L, Ho JWK, Chen J, Xiong N. Aberrant Expression of Circulating MicroRNA Leads to the Dysregulation of Alpha-Synuclein and Other Pathogenic Genes in Parkinson's Disease. Front Cell Dev Biol 2021;9:695007. [PMID: 34497805 DOI: 10.3389/fcell.2021.695007] [Reference Citation Analysis]
33 Pfeiffer RF, Isaacson SH, Pahwa R. Clinical implications of gastric complications on levodopa treatment in Parkinson's disease. Parkinsonism Relat Disord 2020;76:63-71. [PMID: 32461054 DOI: 10.1016/j.parkreldis.2020.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
34 Foffani G, Trigo‐damas I, Pineda‐pardo JA, Blesa J, Rodríguez‐rojas R, Martínez‐fernández R, Obeso JA. Focused ultrasound in Parkinson's disease: A twofold path toward disease modification. Mov Disord 2019;34:1262-73. [DOI: 10.1002/mds.27805] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
35 Mulders AEP, van der Velden RMJ, Drukker M, Broen MPG, Kuijf ML, Leentjens AFG. Usability of the Experience Sampling Method in Parkinson's Disease on a Group and Individual Level. Mov Disord 2020;35:1145-52. [PMID: 32472594 DOI: 10.1002/mds.28028] [Reference Citation Analysis]
36 Wang Z, Wang C, He B, Zhang W, Liu L, Deng M, Lü M, Qi X, Liang S. Determination of Daphnetin and its 8-O-Methylated Metabolite in Rat Plasma by UFLC-MS/MS: Application to a Pharmacokinetic Study. Chromatographia. [DOI: 10.1007/s10337-022-04131-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Wang J, Wang W, Yan C, Luo J, Zhang G. Predicting Drug-Disease Association Based on Ensemble Strategy. Front Genet 2021;12:666575. [PMID: 34012464 DOI: 10.3389/fgene.2021.666575] [Reference Citation Analysis]
38 Kelly MJ, Lawton MA, Baig F, Ruffmann C, Barber TR, Lo C, Klein JC, Ben-Shlomo Y, Hu MT. Predictors of motor complications in early Parkinson's disease: A prospective cohort study. Mov Disord 2019;34:1174-83. [PMID: 31283854 DOI: 10.1002/mds.27783] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
39 Wu J, Xu X, Zheng L, Mo J, Jin X, Bao Y. Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson's disease models. Int Immunopharmacol 2021;99:108025. [PMID: 34364303 DOI: 10.1016/j.intimp.2021.108025] [Reference Citation Analysis]
40 Pike AF, Szabò I, Veerhuis R, Bubacco L. The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson's disease. NPJ Parkinsons Dis 2022;8:32. [PMID: 35332154 DOI: 10.1038/s41531-022-00293-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Megariotis G, Romanos N, Avramopoulos A, Mikaelian G, Theodorou DN. In silico study of levodopa in hydrated lipid bilayers at the atomistic level. J Mol Graph Model 2021;107:107972. [PMID: 34174554 DOI: 10.1016/j.jmgm.2021.107972] [Reference Citation Analysis]
42 Wylie SA, van Wouwe NC, Godfrey SG, Bissett PG, Logan GD, Kanoff KE, Claassen DO, Neimat JS, van den Wildenberg WP. Dopaminergic medication shifts the balance between going and stopping in Parkinson's disease. Neuropsychologia 2018;109:262-9. [DOI: 10.1016/j.neuropsychologia.2017.12.032] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
43 Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P. Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. Expert Rev Neurother 2021;21:1019-33. [PMID: 34525893 DOI: 10.1080/14737175.2021.1968298] [Reference Citation Analysis]
44 Lewitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-hilaire M, Pourcher E, Lopez-manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Neurology 2019;18:145-54. [DOI: 10.1016/s1474-4422(18)30405-8] [Cited by in Crossref: 39] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
45 Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, De Deurwaerdère P, Ko WK, Simola N, Morelli M, Groc L, Rodriguez MC, Gurevich EV, Quik M, Morari M, Mellone M, Gardoni F, Tronci E, Guehl D, Tison F, Crossman AR, Kang UJ, Steece-Collier K, Fox S, Carta M, Angela Cenci M, Bézard E. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Prog Neurobiol 2015;132:96-168. [PMID: 26209473 DOI: 10.1016/j.pneurobio.2015.07.002] [Cited by in Crossref: 254] [Cited by in F6Publishing: 235] [Article Influence: 36.3] [Reference Citation Analysis]
46 Boucherie DM, Duarte GS, Machado T, Faustino PR, Sampaio C, Rascol O, Ferreira JJ. Parkinson's Disease Drug Development Since 1999: A Story of Repurposing and Relative Success. J Parkinsons Dis 2021;11:421-9. [PMID: 33459662 DOI: 10.3233/JPD-202184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Seeberger LC, Hauser RA. Carbidopa levodopa enteral suspension. Expert Opin Pharmacother 2015;16:2807-17. [PMID: 26595228 DOI: 10.1517/14656566.2015.1111336] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
48 Mansoor S, Kayik G, Durdagi S, Sensoy O. Mechanistic insight into the impact of a bivalent ligand on the structure and dynamics of a GPCR oligomer. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.01.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 van der Velden RMJ, Broen MPG, Kuijf ML, Leentjens AFG. Frequency of mood and anxiety fluctuations in Parkinson's disease patients with motor fluctuations: A systematic review: Mood and Anxiety Fluctuations in PD. Mov Disord 2018;33:1521-7. [DOI: 10.1002/mds.27465] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
50 Thomas I, Memedi M, Westin J, Nyholm D. The effect of continuous levodopa treatment during the afternoon hours. Acta Neurol Scand 2019;139:70-5. [PMID: 30180267 DOI: 10.1111/ane.13020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
51 Bilbault T, Taylor S, Walker R, Grundy SL, Pappert EJ, Agro A. Buccal mucosal irritation studies of sublingual apomorphine film (APL-130277) in Syrian golden hamsters. Therapeutic Delivery 2016;7:611-8. [DOI: 10.4155/tde-2016-0043] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
52 Scavone C, Stelitano B, Rafaniello C, Rossi F, Sportiello L, Capuano A. Drugs-Induced Pathological Gambling: An Analysis of Italian Spontaneous Reporting System. J Gambl Stud 2020;36:85-96. [PMID: 30671764 DOI: 10.1007/s10899-019-09828-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
53 Karimi A, Elmi M, Shiri Z, Baharvand H. Therapeutic potential of pluripotent stem cell-derived dopaminergic progenitors in Parkinson's disease: a systematic review protocol. Syst Rev 2021;10:188. [PMID: 34172098 DOI: 10.1186/s13643-021-01736-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Sabourin S, Khazen O, DiMarzio M, Staudt MD, Williams L, Gillogly M, Durphy J, Hanspal EK, Adam OR, Pilitsis JG. Effect of Directional Deep Brain Stimulation on Sensory Thresholds in Parkinson's Disease. Front Hum Neurosci 2020;14:217. [PMID: 32581755 DOI: 10.3389/fnhum.2020.00217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Hauser RA, Isaacson SH, Ellenbogen A, Safirstein BE, Truong DD, Komjathy SF, Kegler-ebo DM, Zhao P, Oh C. Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease. Parkinsonism & Related Disorders 2019;64:175-80. [DOI: 10.1016/j.parkreldis.2019.03.026] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
56 Xie J, Chen S, Bopassa JC, Banerjee S. Drosophila tubulin polymerization promoting protein mutants reveal pathological correlates relevant to human Parkinson's disease. Sci Rep 2021;11:13614. [PMID: 34193896 DOI: 10.1038/s41598-021-92738-3] [Reference Citation Analysis]
57 Fan D, Liu L, Wu Z, Cao M. Combating Neurodegenerative Diseases with the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential. Curr Neuropharmacol 2019;17:563-79. [PMID: 29676231 DOI: 10.2174/1570159X16666180419141613] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
58 Kawano M, Saika K, Takagi R, Matsui M, Matsushita S. Tannic acid acts as an agonist of the dopamine D2L receptor, regulates immune responses, and ameliorates experimentally induced colitis in mice. Brain Behav Immun Health 2020;5:100071. [PMID: 34589853 DOI: 10.1016/j.bbih.2020.100071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
59 Mueller K, Jech R, Růžička F, Holiga Š, Ballarini T, Bezdicek O, Möller HE, Vymazal J, Růžička E, Schroeter ML, Urgošík D. Brain connectivity changes when comparing effects of subthalamic deep brain stimulation with levodopa treatment in Parkinson's disease. Neuroimage Clin 2018;19:1025-35. [PMID: 30035027 DOI: 10.1016/j.nicl.2018.05.006] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 5.8] [Reference Citation Analysis]
60 Zhang R, Li J, Wu Y, Liang S, Xu L. Association of Multiple Dopamine D3 Receptor Gene 3'UTR Polymorphisms with Susceptibility to Parkinson's Disease and Clinical Efficacy of Piribedil Therapy. Genet Test Mol Biomarkers 2021;25:20-30. [PMID: 33372861 DOI: 10.1089/gtmb.2020.0195] [Reference Citation Analysis]
61 Malek N, Kanavou S, Lawton MA, Pitz V, Grosset KA, Bajaj N, Barker RA, Ben-shlomo Y, Burn DJ, Foltynie T, Hardy J, Williams NM, Wood N, Morris HR, Grosset DG. L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. Parkinsonism & Related Disorders 2019;65:55-61. [DOI: 10.1016/j.parkreldis.2019.05.022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
62 Miyaue N, Yabe H, Nagai M. Gastrointestinal surgery improved the absorption of levodopa in Parkinson's disease. Parkinsonism Relat Disord 2021;87:20-1. [PMID: 33932705 DOI: 10.1016/j.parkreldis.2021.04.009] [Reference Citation Analysis]
63 Kwak N, Park J, Kang HY, Lee MJ, Suh JK, Lee H. Efficacy and Safety of Opicapone for Motor Fluctuations as an Adjuvant to Levodopa Therapy in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis. J Parkinsons Dis 2022;12:773-83. [PMID: 35180134 DOI: 10.3233/JPD-213057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Yan Y, Li Y, Liu X, Zhang L, Wang L, Chang Y. Analysis of factors associated with brittle response in patients with Parkinson's disease. Ann Clin Transl Neurol 2020;7:677-82. [PMID: 32352220 DOI: 10.1002/acn3.51028] [Reference Citation Analysis]
65 Kermanizadeh A, Powell LG, Stone V, Møller P. Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape. Int J Nanomedicine 2018;13:7575-605. [PMID: 30510419 DOI: 10.2147/IJN.S177418] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
66 Lewitt PA, Hauser RA, Grosset DG, Stocchi F, Saint-hilaire M, Ellenbogen A, Leinonen M, Hampson NB, Defeo-fraulini T, Freed MI, Kieburtz KD. A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease: Inhaled Levodopa (CVT-301) for Fluctuating PD. Mov Disord 2016;31:1356-65. [DOI: 10.1002/mds.26611] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 8.5] [Reference Citation Analysis]
67 Rodrigues Ribeiro G, Heitor Campos C, Barbosa Câmara-souza M, Fraga do Amaral C, Rodrigues Garcia RCM. Masticatory function and oral sensorimotor ability in Parkinson's disease: Levodopa on versus off periods. SPECIAL CARE IN DENTISTRY 2019;39:77-83. [DOI: 10.1111/scd.12351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Ramot Y, Nyska A, Adar L, Durlach C, Fishelovitch D, Sacco G, Manno RA, Oren S, Perlstein I, Yacobi-zeevi O. ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability. CNS Drugs 2018;32:443-54. [DOI: 10.1007/s40263-018-0512-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
69 Postila PA, Róg T. A Perspective: Active Role of Lipids in Neurotransmitter Dynamics. Mol Neurobiol 2020;57:910-25. [PMID: 31595461 DOI: 10.1007/s12035-019-01775-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
70 LeWitt PA, Verhagen Metman L, Rubens R, Khanna S, Kell S, Gupta S. Effect of Concomitant Medications on the Safety and Efficacy of Extended-Release Carbidopa-Levodopa (IPX066) in Patients With Advanced Parkinson Disease: A Post Hoc Analysis. Clin Neuropharmacol 2018;41:47-55. [PMID: 29432286 DOI: 10.1097/WNF.0000000000000269] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
71 Jiang R, Yang J, Mei S, Zhao Z. Determination of levodopa by chromatography-based methods in biological samples: a review. Anal Sci 2022. [PMID: 35715690 DOI: 10.1007/s44211-022-00132-4] [Reference Citation Analysis]
72 Tambasco N, Romoli M, Calabresi P. Levodopa in Parkinson's Disease: Current Status and Future Developments. Curr Neuropharmacol 2018;16:1239-52. [PMID: 28494719 DOI: 10.2174/1570159X15666170510143821] [Cited by in Crossref: 52] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
73 Li Z, Li X, He X, Jia X, Zhang X, Lu B, Zhao J, Lu J, Chen L, Dong Z, Liu K, Dong Z. Proteomics Reveal the Inhibitory Mechanism of Levodopa Against Esophageal Squamous Cell Carcinoma. Front Pharmacol 2020;11:568459. [PMID: 33101026 DOI: 10.3389/fphar.2020.568459] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Martins D, Mehta MA, Prata D. The “highs and lows” of the human brain on dopaminergics: Evidence from neuropharmacology. Neuroscience & Biobehavioral Reviews 2017;80:351-71. [DOI: 10.1016/j.neubiorev.2017.06.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
75 Colamartino M, Duranti G, Ceci R, Sabatini S, Testa A, Cozzi R. A multi-biomarker analysis of the antioxidant efficacy of Parkinson's disease therapy. Toxicology in Vitro 2018;47:1-7. [DOI: 10.1016/j.tiv.2017.10.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
76 Huang J, Hong W, Yang Z, Ding J, Ren Y. Efficacy of pramipexole combined with levodopa for Parkinson's disease treatment and their effects on QOL and serum TNF-α levels. J Int Med Res 2020;48:300060520922449. [PMID: 32735501 DOI: 10.1177/0300060520922449] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
77 Loiodice S, Denibaud AS, Deffains W, Alix M, Montagne P, Seffals M, Drieu La Rochelle C. Validation of a New Scoring Scale for Behavioral Assessment of L-Dopa-Induced Dyskinesia in the Rat: A New Tool for Early Decision-Making in Drug Development. ACS Chem Neurosci 2018;9:762-72. [PMID: 29226687 DOI: 10.1021/acschemneuro.7b00426] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
78 Jin W, Qazi TJ, Quan Z, Li N, Qing H. Dysregulation of Transcription Factors: A Key Culprit Behind Neurodegenerative Disorders. Neuroscientist 2019;25:548-65. [PMID: 30484370 DOI: 10.1177/1073858418811787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
79 Reis J, Cagide F, Valencia ME, Teixeira J, Bagetta D, Pérez C, Uriarte E, Oliveira PJ, Ortuso F, Alcaro S, Rodríguez-franco MI, Borges F. Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors. European Journal of Medicinal Chemistry 2018;158:781-800. [DOI: 10.1016/j.ejmech.2018.07.056] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
80 Naitou K, Nakamori H, Shiina T, Ikeda A, Nozue Y, Sano Y, Yokoyama T, Yamamoto Y, Yamada A, Akimoto N, Furue H, Shimizu Y. Stimulation of dopamine D2-like receptors in the lumbosacral defaecation centre causes propulsive colorectal contractions in rats. J Physiol 2016;594:4339-50. [PMID: 26999074 DOI: 10.1113/JP272073] [Cited by in Crossref: 18] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Nuzzo T, Punzo D, Devoto P, Rosini E, Paciotti S, Sacchi S, Li Q, Thiolat ML, Véga C, Carella M, Carta M, Gardoni F, Calabresi P, Pollegioni L, Bezard E, Parnetti L, Errico F, Usiello A. The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson's disease patients. Sci Rep 2019;9:8898. [PMID: 31222058 DOI: 10.1038/s41598-019-45419-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
82 Hauser RA, LeWitt PA, Comella CL. On demand therapy for Parkinson's disease patients: Opportunities and choices. Postgrad Med 2021;133:721-7. [PMID: 34082655 DOI: 10.1080/00325481.2021.1936087] [Reference Citation Analysis]
83 Mohammed SG, Qoronfleh MW. Seeds. Adv Neurobiol 2020;24:421-67. [PMID: 32006367 DOI: 10.1007/978-3-030-30402-7_13] [Reference Citation Analysis]
84 Dong X, Zheng D, Nao J. Measurement of serum cystatin C: A valuable tool for evaluating dyskinesia in Parkinson's disease. Neurosci Lett 2019;705:172-6. [PMID: 31054924 DOI: 10.1016/j.neulet.2019.05.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
85 Shaltiel-Karyo R, Caraco Y, Zawaznik E, Weinstock I, Nemas M, Oren S, Yacoby-Zeevi O, LeWitt PA. Subcutaneous Administration of Carbidopa Enhances Oral Levodopa Pharmacokinetics: A Series of Studies Conducted in Pigs, Mice, and Healthy Volunteers. Clin Neuropharmacol 2019;42:111-6. [PMID: 31192808 DOI: 10.1097/WNF.0000000000000345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Bowerman M. Recent Advances and Future Perspectives in the Development of Therapeutic Approaches for Neurodegenerative Diseases. Brain Sci 2020;10:E633. [PMID: 32932920 DOI: 10.3390/brainsci10090633] [Reference Citation Analysis]
87 Wirdefeldt K, Odin P, Nyholm D. Levodopa–Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review. CNS Drugs 2016;30:381-404. [DOI: 10.1007/s40263-016-0336-5] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
88 Simões RM, Castro Caldas A, Ferreira JJ. Inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease. Expert Rev Clin Pharmacol 2020;13:85-101. [PMID: 32011195 DOI: 10.1080/17512433.2020.1724535] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
89 Nedorubov AA, Pavlov AN, Pyatigorskaya NV, Brkich GE, Shabalina MM. Pharmacokinetics of Nanosomal Form of Levodopa in Intranasal Administration. Open Access Maced J Med Sci 2019;7:3509-13. [PMID: 32010367 DOI: 10.3889/oamjms.2019.749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
90 Hughes G. Friendly pharmacodynamics: A simple introduction. Nurse Prescribing 2016;14:34-43. [DOI: 10.12968/npre.2016.14.1.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
91 Torres-Ortega PV, Saludas L, Hanafy AS, Garbayo E, Blanco-Prieto MJ. Micro- and nanotechnology approaches to improve Parkinson's disease therapy. J Control Release 2019;295:201-13. [PMID: 30579984 DOI: 10.1016/j.jconrel.2018.12.036] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
92 Solís O, García-Montes JR, Garcia-Sanz P, Herranz AS, Asensio MJ, Kang G, Hiroi N, Moratalla R. Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice. Neurobiol Dis 2017;102:133-9. [PMID: 28315782 DOI: 10.1016/j.nbd.2017.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
93 Shiraishi T, Nishikawa N, Mukai Y, Takahashi Y. High levodopa plasma concentration after oral administration predicts levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2020;75:80-4. [PMID: 32497995 DOI: 10.1016/j.parkreldis.2020.05.022] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Kilinçalp G, Sjöström AC, Eriksson B, Holmberg B, Constantinescu R, Bergquist F. Predictive Value of Ambulatory Objective Movement Measurement for Outcomes of Levodopa/Carbidopa Intestinal Gel Infusion. J Pers Med 2022;12:27. [PMID: 35055343 DOI: 10.3390/jpm12010027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Vodičková A, Koren SA, Wojtovich AP. Site-specific mitochondrial dysfunction in neurodegeneration. Mitochondrion 2022:S1567-7249(22)00010-1. [PMID: 35182728 DOI: 10.1016/j.mito.2022.02.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Brognara L, Navarro-Flores E, Iachemet L, Serra-Catalá N, Cauli O. Beneficial Effect of Foot Plantar Stimulation in Gait Parameters in Individuals with Parkinson's Disease. Brain Sci 2020;10:E69. [PMID: 32012779 DOI: 10.3390/brainsci10020069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
97 Stefani A, Pierantozzi M, Cardarelli S, Stefani L, Cerroni R, Conti M, Garasto E, Mercuri NB, Marini C, Sucapane P. Neurotrophins as Therapeutic Agents for Parkinson’s Disease; New Chances From Focused Ultrasound? Front Neurosci 2022;16:846681. [DOI: 10.3389/fnins.2022.846681] [Reference Citation Analysis]
98 Zhang B, Yan W, Zhu Y, Yang W, Le W, Chen B, Zhu R, Cheng L. Nanomaterials in Neural-Stem-Cell-Mediated Regenerative Medicine: Imaging and Treatment of Neurological Diseases. Adv Mater 2018;30:e1705694. [PMID: 29543350 DOI: 10.1002/adma.201705694] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
99 Azevedo Kauppila L, Pimenta Silva D, Ferreira JJ. Clinical Utility of Opicapone in the Management of Parkinson's Disease: A Short Review on Emerging Data and Place in Therapy. Degener Neurol Neuromuscul Dis 2021;11:29-40. [PMID: 34007239 DOI: 10.2147/DNND.S256722] [Reference Citation Analysis]
100 Wang Y, Yao L, Gao S, Zhang G, Zhang Q, Liu W, Zhou Y, Sun Y, Feng J, Liu J. Inhibition of striatal dopamine D5 receptor attenuates levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain Res 2021;1754:147266. [PMID: 33422541 DOI: 10.1016/j.brainres.2020.147266] [Reference Citation Analysis]
101 Memedi M, Sadikov A, Groznik V, Žabkar J, Možina M, Bergquist F, Johansson A, Haubenberger D, Nyholm D. Automatic Spiral Analysis for Objective Assessment of Motor Symptoms in Parkinson's Disease. Sensors (Basel) 2015;15:23727-44. [PMID: 26393595 DOI: 10.3390/s150923727] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
102 Wollmer E, Klein S. A review of patient-specific gastrointestinal parameters as a platform for developing in vitro models for predicting the in vivo performance of oral dosage forms in patients with Parkinson’s disease. International Journal of Pharmaceutics 2017;533:298-314. [DOI: 10.1016/j.ijpharm.2017.08.126] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
103 Teixeira FG, Gago MF, Marques P, Moreira PS, Magalhães R, Sousa N, Salgado AJ. Safinamide: a new hope for Parkinson's disease? Drug Discov Today 2018;23:736-44. [PMID: 29339106 DOI: 10.1016/j.drudis.2018.01.033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
104 Hoekman J, Ray S, Aurora SK, Shrewsbury SB; Impel NeuroPharma, Inc., Seattle, WA, USA, Impel NeuroPharma, Inc., Seattle, WA, USA, Impel NeuroPharma, Inc., Seattle, WA, USA, Impel NeuroPharma, Inc., Seattle, WA, USA. The Upper Nasal Space—A Novel Delivery Route Ideal for Central Nervous System Drugs. US Neurology 2020;16:25. [DOI: 10.17925/usn.2020.16.1.25] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Angela Cenci M, Skovgård K, Odin P. Non-dopaminergic approaches to the treatment of motor complications in Parkinson's disease. Neuropharmacology 2022. [DOI: 10.1016/j.neuropharm.2022.109027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Yang B, Wang X, Mo J, Li Z, Gao D, Bai Y, Zou L, Zhang X, Zhao X, Wang Y, Liu C, Zhao B, Guo Z, Zhang C, Hu W, Zhang J, Zhang K. The amplitude of low-frequency fluctuation predicts levodopa treatment response in patients with Parkinson's disease. Parkinsonism Relat Disord 2021;92:26-32. [PMID: 34666272 DOI: 10.1016/j.parkreldis.2021.10.003] [Reference Citation Analysis]
107 van Wouwe NC, Kanoff KE, Claassen DO, Spears CA, Neimat J, van den Wildenberg WP, Wylie SA. Dissociable Effects of Dopamine on the Initial Capture and the Reactive Inhibition of Impulsive Actions in Parkinson's Disease. J Cogn Neurosci 2016;28:710-23. [PMID: 26836515 DOI: 10.1162/jocn_a_00930] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
108 Gao CQ, Zhou YK, Xin XH, Min H, Du PF. DDA-SKF: Predicting Drug-Disease Associations Using Similarity Kernel Fusion. Front Pharmacol 2021;12:784171. [PMID: 35095495 DOI: 10.3389/fphar.2021.784171] [Reference Citation Analysis]
109 Ferreira-Junior NC, Campos AC, Guimarães FS, Del-Bel E, Zimmermann PMDR, Brum Junior L, Hallak JE, Crippa JA, Zuardi AW. Biological bases for a possible effect of cannabidiol in Parkinson's disease. Braz J Psychiatry 2020;42:218-24. [PMID: 31314869 DOI: 10.1590/1516-4446-2019-0460] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
110 Timpka J, Nitu B, Datieva V, Odin P, Antonini A. Device-Aided Treatment Strategies in Advanced Parkinson's Disease. Parkinson's Disease. Elsevier; 2017. pp. 453-74. [DOI: 10.1016/bs.irn.2017.03.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
111 Bestetti A, Capozza A, Lacerenza M, Manfredi L, Mancini F. Delayed Gastric Emptying in Advanced Parkinson Disease: Correlation With Therapeutic Doses. Clin Nucl Med 2017;42:83-7. [PMID: 27941374 DOI: 10.1097/RLU.0000000000001470] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
112 Espay AJ, Pagan FL, Walter BL, Morgan JC, Elmer LW, Waters CH, Agarwal P, Dhall R, Ondo WG, Klos KJ, Silver DE. Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy. Neurol Clin Pract 2017;7:86-93. [PMID: 28243505 DOI: 10.1212/CPJ.0000000000000316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
113 Fackrell R, Carroll CB, Grosset DG, Mohamed B, Reddy P, Parry M, Chaudhuri KR, Foltynie T. Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists. Neurodegener Dis Manag 2018;8:349-60. [PMID: 29975112 DOI: 10.2217/nmt-2018-0020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
114 Beckers M, Bloem BR, Verbeek MM. Mechanisms of peripheral levodopa resistance in Parkinson's disease. NPJ Parkinsons Dis 2022;8:56. [PMID: 35546556 DOI: 10.1038/s41531-022-00321-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Fahn S, Poewe W. Levodopa: 50 years of a revolutionary drug for Parkinson disease. Mov Disord 2015;30:1-3. [PMID: 25488146 DOI: 10.1002/mds.26122] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
116 Falconi A, Bonito-Oliva A, Di Bartolomeo M, Massimini M, Fattapposta F, Locuratolo N, Dainese E, Pascale E, Fisone G, D'Addario C. On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinson's Disease. Front Neurosci 2019;13:683. [PMID: 31354407 DOI: 10.3389/fnins.2019.00683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
117 Nie T, He Z, Zhu J, Chen K, Howard GP, Pacheco-torres J, Minn I, Zhao P, Bhujwalla ZM, Mao H, Liu L, Chen Y. Non-invasive delivery of levodopa-loaded nanoparticles to the brain via lymphatic vasculature to enhance treatment of Parkinson’s disease. Nano Res 2021;14:2749-61. [DOI: 10.1007/s12274-020-3280-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Laurencin C, Danaila T, Broussolle E, Thobois S. Initial treatment of Parkinson's disease in 2016: The 2000 consensus conference revisited. Rev Neurol (Paris) 2016;172:512-23. [PMID: 27476416 DOI: 10.1016/j.neurol.2016.07.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
119 Morio H, Reien Y, Hirayama Y, Hashimoto H, Anzai N. Protein kinase C activation upregulates human L-type amino acid transporter 2 function. J Physiol Sci 2021;71:11. [PMID: 33789576 DOI: 10.1186/s12576-021-00795-0] [Reference Citation Analysis]
120 Alfonsetti M, Castelli V, d'Angelo M. Are We What We Eat? Impact of Diet on the Gut-Brain Axis in Parkinson's Disease. Nutrients 2022;14:380. [PMID: 35057561 DOI: 10.3390/nu14020380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
121 Fan CH, Wei KC, Chiu NH, Liao EC, Wang HC, Wu RY, Ho YJ, Chan HL, Wang TA, Huang YZ, Hsieh TH, Lin CH, Lin YC, Yeh CK. Sonogenetic-Based Neuromodulation for the Amelioration of Parkinson's Disease. Nano Lett 2021;21:5967-76. [PMID: 34264082 DOI: 10.1021/acs.nanolett.1c00886] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Vijayakumar D, Jankovic J. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs 2016;76:759-77. [PMID: 27091215 DOI: 10.1007/s40265-016-0566-3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 11.0] [Reference Citation Analysis]
123 Verhagen Metman L, Stover N, Chen C, Cowles VE, Sweeney M. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease: GASTRORETENTIVE LEVODOPA FOR PARKINSON'S. Mov Disord 2015;30:1222-8. [DOI: 10.1002/mds.26219] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
124 Brás EJS, Domingues C, Chu V, Fernandes P, Conde JP. Microfluidic bioreactors for enzymatic synthesis in packed-bed reactors-Multi-step reactions and upscaling. J Biotechnol 2020;323:24-32. [PMID: 32712128 DOI: 10.1016/j.jbiotec.2020.07.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
125 Wang JT, Rodrigo AC, Patterson AK, Hawkins K, Aly MMS, Sun J, Al Jamal KT, Smith DK. Enhanced Delivery of Neuroactive Drugs via Nasal Delivery with a Self-Healing Supramolecular Gel. Adv Sci (Weinh) 2021;8:e2101058. [PMID: 34029010 DOI: 10.1002/advs.202101058] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
126 Shu Z, Pang P, Wu X, Cui S, Xu Y, Zhang M. An Integrative Nomogram for Identifying Early-Stage Parkinson's Disease Using Non-motor Symptoms and White Matter-Based Radiomics Biomarkers From Whole-Brain MRI. Front Aging Neurosci 2020;12:548616. [PMID: 33390927 DOI: 10.3389/fnagi.2020.548616] [Reference Citation Analysis]
127 Riccardi C, Napolitano F, Montesarchio D, Sampaolo S, Melone MAB. Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics 2021;13:1897. [PMID: 34834311 DOI: 10.3390/pharmaceutics13111897] [Reference Citation Analysis]
128 LeWitt PA, Fahn S. Levodopa therapy for Parkinson disease: A look backward and forward. Neurology 2016;86:S3-12. [PMID: 27044648 DOI: 10.1212/WNL.0000000000002509] [Cited by in Crossref: 89] [Cited by in F6Publishing: 33] [Article Influence: 14.8] [Reference Citation Analysis]
129 Chtioui H, Sadowski SM, Winzeler B, Tschopp O, Grouzmann E, Abid K. High concentration of plasma methoxytyramine: dopamine-producing tumour or Parkinson's disease therapy? Ann Clin Biochem 2019;56:466-71. [PMID: 30974961 DOI: 10.1177/0004563219835263] [Reference Citation Analysis]
130 Kawano M, Takagi R, Saika K, Matsui M, Matsushita S. Dopamine regulates cytokine secretion during innate and adaptive immune responses. Int Immunol 2018;30:591-606. [PMID: 30165447 DOI: 10.1093/intimm/dxy057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
131 Lipp MM, Hickey AJ, Langer R, LeWitt PA. A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson's disease. Expert Opin Drug Deliv 2021;:1-11. [PMID: 34311641 DOI: 10.1080/17425247.2021.1960820] [Reference Citation Analysis]
132 Olanow CW, Poewe W, Rascol O, Stocchi F. On-Demand Therapy for OFF Episodes in Parkinson's Disease. Mov Disord 2021. [PMID: 34363424 DOI: 10.1002/mds.28726] [Reference Citation Analysis]
133 LeWitt PA, Pahwa R, Sedkov A, Corbin A, Batycky R, Murck H. Pulmonary Safety and Tolerability of Inhaled Levodopa (CVT-301) Administered to Patients with Parkinson's Disease. J Aerosol Med Pulm Drug Deliv 2018;31:155-61. [PMID: 29161531 DOI: 10.1089/jamp.2016.1354] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
134 Wang L, Xiong N, Huang J, Guo S, Liu L, Han C, Zhang G, Jiang H, Ma K, Xia Y, Xu X, Li J, Liu JY, Wang T. Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease. Front Aging Neurosci 2017;9:206. [PMID: 28701947 DOI: 10.3389/fnagi.2017.00206] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
135 Wang X, Xiong Y, Lin J, Lou X. Target Selection for Magnetic Resonance-Guided Focused Ultrasound in the Treatment of Parkinson's Disease. J Magn Reson Imaging 2022. [PMID: 35081263 DOI: 10.1002/jmri.28080] [Reference Citation Analysis]
136 Han C, Chaineau M, Chen CX, Beitel LK, Durcan TM. Open Science Meets Stem Cells: A New Drug Discovery Approach for Neurodegenerative Disorders. Front Neurosci 2018;12:47. [PMID: 29467610 DOI: 10.3389/fnins.2018.00047] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
137 Lewitt PA, Giladi N, Navon N. Pharmacokinetics and efficacy of a novel formulation of carbidopa-levodopa (Accordion Pill®) in Parkinson's disease. Parkinsonism & Related Disorders 2019;65:131-8. [DOI: 10.1016/j.parkreldis.2019.05.032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
138 Hansen RN, Suh K, Serbin M, Yonan C, Sullivan SD. Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. J Med Econ 2021;24:563-9. [PMID: 33866942 DOI: 10.1080/13696998.2021.1916750] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Giladi N, Gurevich T, Djaldetti R, Adar L, Case R, Leibman-Barak S, Sasson N, Caraco Y. ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study. Parkinsonism Relat Disord 2021;91:139-45. [PMID: 34619438 DOI: 10.1016/j.parkreldis.2021.09.024] [Reference Citation Analysis]
140 Urbizu A, Beyer K. Epigenetics in Lewy Body Diseases: Impact on Gene Expression, Utility as a Biomarker, and Possibilities for Therapy. Int J Mol Sci 2020;21:E4718. [PMID: 32630630 DOI: 10.3390/ijms21134718] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
141 Fabbri M, Ferreira JJ, Lees A, Stocchi F, Poewe W, Tolosa E, Rascol O. Opicapone for the treatment of Parkinson's disease: A review of a new licensed medicine. Mov Disord 2018;33:1528-39. [PMID: 30264443 DOI: 10.1002/mds.27475] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 8.8] [Reference Citation Analysis]
142 Grimm O, Nägele M, Küpper-Tetzel L, de Greck M, Plichta M, Reif A. No effect of a dopaminergic modulation fMRI task by amisulpride and L-DOPA on reward anticipation in healthy volunteers. Psychopharmacology (Berl) 2021;238:1333-42. [PMID: 33140215 DOI: 10.1007/s00213-020-05693-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
143 Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JA. Advances in understanding genomic markers and pharmacogenetics of Parkinson's disease. Expert Opin Drug Metab Toxicol 2016;12:433-48. [PMID: 26910127 DOI: 10.1517/17425255.2016.1158250] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
144 Fietzek UM, Schulz SJ, Ziegler K, Ceballos-Baumann AO. The Minimal Clinically Relevant Change of the FOG Score. J Parkinsons Dis 2020;10:325-32. [PMID: 31868684 DOI: 10.3233/JPD-191783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
145 Muthuraman M, Koirala N, Ciolac D, Pintea B, Glaser M, Groppa S, Tamás G, Groppa S. Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease. Front Neurol 2018;9:711. [PMID: 30210436 DOI: 10.3389/fneur.2018.00711] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
146 Fabbri M, Rosa MM, Abreu D, Ferreira JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Neurodegenerative Disease Management 2015;5:481-96. [DOI: 10.2217/nmt.15.46] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
147 Zhao DF, Fan YF, Yu HN, Hou FB, Xiang YW, Wang P, Ge GB, Yang L, Xu JG. Discovery and characterization of flavonoids in vine tea as catechol-O-methyltransferase inhibitors. Fitoterapia 2021;152:104913. [PMID: 33932529 DOI: 10.1016/j.fitote.2021.104913] [Reference Citation Analysis]